Product
Ad26.COV2.S
Aliases
Ad26COVS1, Janssen, JNJ-78436735, JNJ-78436735, Ad26COVS1 (1 other aliases)
14 clinical trials
14 indications
Indication
COVID-19Indication
HealthyIndication
Adverse Reaction to ImmunizationIndication
Adverse Vaccine ReactionIndication
Rheumatoid ArthritisIndication
Systemic Lupus Erythematosus (SLE)Indication
Pemphigus vulgarisIndication
Multiple SclerosisIndication
Systemic SclerosisIndication
Pediatric Systemic Lupus ErythematosusIndication
Juvenile Idiopathic Arthritis (JIA)Indication
Juvenile DermatomyositisClinical trial
A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2Status: Completed, Estimated PCD: 2021-10-27
Clinical trial
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant ParticipantsStatus: Completed, Estimated PCD: 2023-11-24
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and OlderStatus: Completed, Estimated PCD: 2022-06-17
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2023-06-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and OlderStatus: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years InclusiveStatus: Completed, Estimated PCD: 2023-08-14
Clinical trial
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy AdultsStatus: Completed, Estimated PCD: 2023-07-10
Clinical trial
A Phase 1 Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of Intradermal and Subcutaneous Application of the Plasmid DNA SARS-CoV-2 Omicron BA.2 Vaccine Alveavax-v1.2 in Primary Ad26.COV2.S Vaccinated Healthy IndividualsStatus: Completed, Estimated PCD: 2023-03-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years InclusiveStatus: Completed, Estimated PCD: 2022-03-09
Clinical trial
A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesStatus: Completed, Estimated PCD: 2023-06-16
Clinical trial
Effectiveness of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine on Symptomatic SARS-CoV-2 Infection and COVID-19-related Hospitalizations, Mortality, and Long-term Consequences in Brazil: a Real-world Evidence StudyStatus: Completed, Estimated PCD: 2022-06-20
Clinical trial
Phase II Trial Evaluating the Immunogenicity and Safety of Ad26.COV2.S Vaccine in Adult Participants in MaliStatus: Active (not recruiting), Estimated PCD: 2022-09-25
Clinical trial
Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)Status: Completed, Estimated PCD: 2023-06-22